Effects of sodium glucose cotransporter-2 inhibitors on serum uric acid in type 2 diabetes mellitus : a systematic review with an indirect comparison meta-analysis

Abstract EN

To describe the effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid (SUA) in patients with type 2 diabetes mellitus (T2DM).

PubMed, EMBASE, and CENTRAL were searched for randomized controlled trials of SGLT2 inhibitors in patients with T2DM up to Aug 10, 2017, without language or date restrictions.

Thirty-one studies totaling 13,650 patients were included.

SGLT2 inhibitors significantly decreased SUA levels compared with placebo, canagliflozin WMD –37.02 lmol/L, 95% CI [–38.41, –35.63], dapagliflozin WMD –38.05 lmol/L, 95% CI [–44.47, –31.62], empagliflozin WMD – 42.07 lmol/L, 95% CI [–46.27, –37.86].

The drug class effect of SUA reduction suggesting SGLT2 inhibitors might be beneficial for diabetic patients with hyperuricemia.